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SHORT COMMUNICATION
Pruritus is the chief symptom in many dermatologic and 
systemic conditions and can be quite burdensome on a 
patient’s health-related quality of life (HRQoL) (1–3). 
ItchyQoL is a validated survey designed to assess the 
pruritus-specific disease burden (4). Although it is un-
derstood that higher scores correspond to higher HRQoL 
impact, the lack of clinical meaning for the scores has 
limited its use outside of research. Such endeavors have 
been performed for skin specific HRQoL measures such 
as the Dermatology Life Quality index (DLQI) (4, 5) and 
Skindex (6), where bands of scores are assigned a level 
of HRQoL impairment. Defining bands of ItchyQoL 
scores in terms of levels of itch-specific HRQoL im-
pairment will provide clinicians with a better gauge of 
both pruritus-specific burden of disease and the efficacy 
of treatment. Researchers will be able to know whether 
new interventions were able to make clinically, and not 
just statistically, significant differences in itch burden 
(7). In this pilot study, we utilized an existing dataset 
and applied methods previously used in assigning clini-
cal meaning for the DLQI to explore possible clinically 
meaningful bands for the ItchyQoL (5, 8).
METHODS
Patients were recruited from the Atlanta VA Medical Center 
outpatient dermatology clinic, with the only inclusion criteria 
being a history of chronic (> 6 weeks duration) pruritus. Sub-
jects completed multiple self-administered written surveys ac-
cessing HRQoL, including ItchyQoL and a Global Itch Severity 
Question (GISQ). 
ItchyQoL is a validated 22-question survey that assesses 
pruritus-specific HRQoL impact on symptoms, functional limi-
tations, and emotions (4). Each of the questions is scored 1–5 (1: 
never; 2: rarely; 3: sometimes; 4: often; 5: all of the time) with 
the sum forming the raw ItchyQol score with a range of 22–110.
A GISQ was used to anchor and thus provide clinical context 
to the ItchyQoL results (7). GISQ is one question where the 
respondents rate their itch on a scale of 0 to 10 with 0 being 
no itch at all, and 10 being the worst itch ever experienced, 
for the past 7 days.
Band formation: Raw ItchyQoL scores were divided into 
10-point intervals (0–10, 11–20, 21–30, etc.), and the mean, 
median, and mode of the GISQ scores of patients included in 
each interval were calculated. Five potential raw ItchyQoL 
band sets were created with effort to distribute the number of 
patients as evenly as possible, but also restricting the number 
of bands for ease of use. GISQ scores were divided into two 
potential sets of intervals.
Correlations of each of the 5 potential ItchyQoL band sets 
with each of the two proposed GISQ breakdowns was calculated 
using the Spearman Rank and Pearson correlation coefficients. 
The kappa, both unweighted and weighted, coefficient of agree-
ment was calculated for the banding system with the highest 
Spearman and Pearson coefficient variables with p < 0.05 con-
sidered statistically significant (9). Analyses were performed 
using SAS 9.2. The anchoring technique was modeled after 
work done on the DLQI (10).
RESULTS
The majority of the 54 subjects were men (85%) and 
Caucasian (79%). The mean ± SD age was 63.8 ± 15.5 
years. The majority (75%) experienced pruritus most 
or all of the time and nearly all (93%) had experienced 
pruritus for greater than 6 months. The overall mean ± SD 
GISQ score was 6.19 ± 2.42 out of 10, and the overall 
mean ± SD raw ItchyQoL score was 57.11 ± 21.06 out of 
110. The Spearman rank coefficient (0.557, p < 0.0001) 
and Pearson correlation coefficient (0.559, p < 0.0001) 
showed a moderate correlation between raw ItchyQoL 
and GISQ scores. The correlation coefficients for all 5 
proposed band sets ranged from 0.428 to 0.574 (Pearson) 
and 0.462 to 0.552 (Spearman). The ItchyQoL Band Set 
and GISQ breakdown with the highest measures of corre-
lation (Pearson = 0.574, Spearman = 0.552) demonstrated 
a қ = –0.2714 and weighted қ = 0.5677. Thus the set of 
ItchyQoL bands and corresponding levels of pruritus-
specific HRQoL impairment are as follows: 0–30 (little), 
31–50 (mild), 51–80 (moderate), and 81–110 (severe). 
These bands are visualized in Fig. 1. 
DISCUSSION
HRQoL instruments elucidate the burden that diseases 
place on patients, but lack of information on the clinical 
interpretation of HRQoL scores limits their clinical use 
(11, 12). This pilot study attempts to address such a 
gap by proposing a set of bands to aid in the clinical 
interpretation of the previously validated ItchyQoL. 
With these bands, we know that if an ItchyQoL raw 
score stays within a band after treatment, say 79 to 
60, even if the change was statistically significant, the 
change would not be clinically significant (moderate 
to moderate impairment).
The anchor-based technique was chosen for its validity 
with short and relatively simple questionnaires (13, 14). 
The sum of all ItchyQoL questions was chosen to derive 
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the 10-point intervals for its simplicity. Using the raw 
ItchyQoL scores is unique to the proposed ItchyQoL 
bands. Currently, ItchyQoL scores are calculated by ta-
king the mean of all 22 questions, but this was thought un-
desirable because it involves decimal points and smaller 
band ranges, making bands more difficult to remember, 
potentially resulting in decreased use. The raw ItchyQoL 
score increases the range of values, but does not affect 
the questionnaire’s presentation to the patient nor the 
instrument’s psychometrics or validity. However, if the 
discrepancy of using the raw score versus the original 
mean scores proves to be a barrier, a future iteration can 
be explored using the mean scores.
Limitations to this pilot study include the small size, 
relatively homogeneous subject population, and single 
recruitment location, thus potentially limiting the gene-
ralizability of the results. Future studies need to include 
larger populations that involve both nonveteran men 
and women, incorporating other age groups. Another 
limitation is that our kappa coefficient shows only a 
moderate agreement between our set of ItchyQoL bands 
and the GISQ. This may be attributable to the small 
number of subjects. Additionally, the GISQ gauges “itch 
severity” during the last 7 days, and does not have the 
multi-dimensionality of the 3-construct ItchyQoL. This 
difference in complexity of the two instruments may 
have contributed to the less than ideal kappa coefficient. 
Nonetheless, the weighted kappa, demonstrated moderate 
agreement despite the small numbers and thus supports 
the potential of the ItchyQoL bands to assess patients’ 
level of impairment. In future expanded studies, it may 
be simpler to use “little, mild, moderate, severe” as 
categorical answers to GISQ in order to map the bands 
and thus not need to guess the cut-off values; or to utilize 
percentiles of the reported rather than the possible scores, 
however a larger sample would be necessary.
In conclusion, the ItchyQoL, with the 3 constructs, is 
a rich instrument capable of elucidating the symptoma-
tic, functional, and emotional burden created by chronic 
pruritus. Never intended as a substitute for ItchyQoL 
construct scores, raw ItchyQoL bands add an additional 
layer of interpretation of the information. The results 
of this pilot study need to be validated with a larger, 
more heterogeneous population, but provide an initial 
means to monitor significant clinical improvement or 
exacerbation of pruritus. 
ACKNOWLEDGEMENT
Conflict of interest: Dr. Chen’s research laboratory at Emory 
University receives royalties for usage of the ItchyQoL.
REFERENCES
1. Koblenzer, CS. Itch and the atopic skin. J Allergy Clin 
Immunol 1999; 104 (Suppl): S109–113.
2. Wolkenstein P, Grob JJ, Bastuji-Garin S, Ruszczynski S, 
Roujeau JC, Revuz J. French people and skin disease: 
results of a survey using a representative sample. Arch 
Dermatol 2003; 139: 1614–1619.
3. Basra MKA, Shahrukh M. Burden of skin diseases. Expert 
Rev Pharmacoecon Outcomes Res 2009; 9: 271–283.
4. Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, 
Swerlick RA, Chen SC. A pilot quality-of-life instrument 
for pruritis. J Am Acad Dermatol 2008; 59: 234–244.
5. Finlay AY, Khan GK. Dermatology Life Quality Index 
(DLQI) – a simple practical measure for routine clinical 
use. Clin Exp Dermatol 1994; 19: 210–216.
6. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski 
SJ. Skindex, a quality-of-life measure for patients with skin 
disease: reliability, validity, and responsiveness. J Invest 
Dermatol 1996; 107: 707–713.
7. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. 
Methods to explain the clinical significance of health status 
measures. Mayo Clin Proc 2002; 77: 371–383.
8. Hongbo Y1, Thomas CL, Harrison MA, Salek MS, Finlay 
AY. Translating the science of quality of life into practice: 
What do dermatology life quality index scores mean? J 
Invest Dermatol 2005; 125: 659–664.
9. Schuster C. A note on the interpretation of weighted kappa 
and its relations to other rater agreement statistics for metric 
scales. Educ Psychol Meas 2004; 64: 243–253.
10. Hahn HB1, Melfi CA, Chuang TY, Lewis CW, Gonin R, 
Hanna MP, Farmer ER. Use of the Dermatology Life Qua-
lity Index (DLQI) in a Midwestern US urban clinic. J Am 
Acad Dermatol 2001; 45: 44–48.
11. de Haes JC, Stiggelbout AM. Assessment of values, utilities 
and preferences in cancer patients. Cancer Treat Rev 1996; 
22 (suppl A): 13–26.
12. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegehalter D, 
Cox D. Quality of life measures in healthcare, I: applica-
tions and issues in assessment. BMJ 1992; 305: 1074–1077. 
13. Lydick E, Epstein RS. Interpretation of quality of life 
changes. Qual Life Res 1993; 2: 221–226.
14. Deyo RA, Patrick DL. The significance of treatment ef-
fects: The clinical perspective. Med Care 1995; 33: SIV 
286–SIV 291.
Fig. 1. Relationship between the raw ItchyQoL score and the mean, median, 
and mode of the Global Itch Severity Question (GISQ) score with proposed 
banding scale (full-drawn line) of ItchyQoL scores.
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